Intarcia Therapeutics a Startup That Develops Therapies for Diseases That Require Long-Term Chronic Treatment

Founders- David Franklin, James M. Ahlers, Thomas Alessi

Founded in- 1995

Hub Tags- Unicorn

CEO- Kurt C. Graves (Apr 2012–)

Revenue- $56M

Headquarters- Boston, Massachusetts, United States

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides.

Intarcia Therapeutics’ products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C, and ITCA 650, a delivery device that provides type 2 diabetes patients long-term steady-state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity.

Intarcia’s drug development expertise and competitive edge are demonstrated by its ability to stabilize proteins and peptides at above-body temperature and deliver them constantly and consistently via Intarcia’s proprietary technology platform. Intarcia is pursuing a Phase III-stage development program for type 2 diabetes and has additional weight regulation programs to control obesity. In addition to those listed above, investors in Intarcia include Alta Partners, Foresite Capital, and Omega Funds.

Suprotik Sinha

Suprotik Sinha is the Content Writer with Synkrama Technologies. He writes about technologies and startups in the global enterprise space. An animal lover, Suprotik, is a postgraduate from Symbiosis Institute of Mass Communication (SIMC) Pune. He carries 6+ years of experience in Content Writing, and he also worked in mainstream broadcast media, where he worked as a Journalist with Ibn7 ( now known as News18 India) and Zee Media in Mumbai.